Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 4, 2004 - Issue 2
Submit an article Journal homepage
13
Views
0
CrossRef citations to date
0
Altmetric
Miscellaneous

Economic benefits of pioglitazone for treating patients with Type 2 diabetes

Loren D Grossman Research and Development, Eli Lilly Canada, Division of Endocrinology and Metabolism, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada. [email protected]
&
Christopher J Longo Government and Economic Affairs, Eli Lilly Canada, Eli Lilly Canada, Toronto, Ontario, Canada. [email protected].
Pages 135-142 | Published online: 09 Jan 2014

References

  • Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can. j Diabetes 27\(Suppl. 2), S1—S3 (2003).
  • ••Comprehensive, evidence-based clinicalpractice guidelines for diabetes care.
  • DeFronzo RA. The triumvirate: 0-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes37, 667–687 (1988).
  • ••Comprehensive review of the majorpathophysiologic mechanisms responsible for the development of Type 2 diabetes and the medications available for its treatment, along with a detailed description of their mechanisms of action.
  • Reaven GM. Insulin resistance and its consequences: noninsulin dependent diabetes mellitus and coronary heart disease. In: Diabetes Mellitus. LeRoith D, Taylor SE, Olefsky JM (Eds). Lippincott-Raven, PA, USA, 509–519 (1996).
  • ADA Consensus Development Conference. Diabetes Cam 21,310 (1998).
  • Kolterman O, Scarlett JA, Olefsky JM. Insulin resistance in noninsulin dependent, Type II diabetes. Clin. Endocrine" Metab.1(1), 363–388 (1982).
  • Shepherd PR, Kahn BB. Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Eng". J. Med. 341, 248–257 (1999).
  • DeFronzo RA. Pharmacologic therapy for Type 2 diabetes mellitus. Ann. Intern. Med.131,281-303 (1999).
  • Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus. JAIVIA 281,2005–2012 (1999).
  • Auwerx J. Review: PPAR, the ultimate thrifty gene. Diabetologia 42,1033–1049 (1999).
  • Desvergne B, Wahli W Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20, 649–688 (1999).
  • Sakamoto J, Kimura H, Moriyama S et al Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem. Biophys. Res. Commun. 278,704–711 (2000).
  • Tan M. How pioglitazone affects glucose and lipid metabolism. Exp. Gila Endocrine" Diabetes 108\(Suppl. 2), S224—S233 (2000).
  • Miyazaki Y, Mahankali A, Matsuda M et al. Improved glycemic control and enhanced insulin sensitivity in Type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24,710–719 (2001).
  • •Clinical trial that reports on the clinical effects and mechanism of action of pioglitazone.
  • Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in Type 2 diabetes. Diabetes Cam 25(3), 517–523 (2002).
  • Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in Type 2 diabetic patients. j Clin. Endocrine" Metab. 87(6), 2784–2791 (2002).
  • Bajaj M, Suraamomkul S, Pratipanawatr T et al Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with Type 2 diabetes. Diabetes 52 (6), 1364–1370 (2003) .
  • Aronoff S, Rosenblatt S, Braithwaite S et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes. Diabetes Cam23, 1605–1611 (2000).
  • Herz M, Johns D, Reviriego J et al. A randomised, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with Type 2 diabetes mellitus. Clin. filer. 25(4), 1074–1095 (2003).
  • Rosenblatt S, Miskin B, Glazer NB et al The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with Type 2 diabetes mellitus. Coronary Artery Dis. 12,419–423 (2001).
  • Matthews DR, Hosker JP, Rudenski AS et al Homeostasis model assessment: insulin resistance and 0-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985).
  • Kipnes MS, Krosnick A, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in the treatment of patients with Type 2 diabetes mellitus: a randomized placebo-controlled study. Am. Med 111,10–17 (2001).
  • Einhorn D, Rendell M, Rosenzweig J et al Pioglitazone hydrochloride in combination with metformin in the treatment of Type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin. Tiler. 22, 1395–1409 (2000).
  • Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. Efficacy and safety of pioglitazone in Type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin. Int. j Clin. Pract. 56(4), 251–257 (2002).
  • Pavo I, Jermendy G, Varkonyi TT et al Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with Type 2 diabetes. j Clin. Endocrine" Metab. 88,1637-1645 (2003).
  • Johns D, Strand J, Halse J et al. The long-term effects of pioglitazone and glibenclamide on glycemic control and insulin sensitivity in patients with Type 2 diabetes. Diabetologia 46 (Suppl. 2), 829 (2003).
  • Tan MH, Herz M, Johns D et al Long-term effects of pioglitazone and glimepiride on insulin sensitivity and glycemic control in patients with Type 2 diabetes. Diabetes Metab. 29,2297 (2003).
  • Nakamura T, Ushiyama C, Shimada N et al. Comparative effects of pioglitazone, glibenclamide and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. j Diab. Comp]. 14, 250–254 (2000).
  • Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism50(10), 1193–1196 (2001).
  • Hirose H, Kawai T, Yamamoto Y et al Effects of pioglitazone on metabolic parameters, body fat distribution and serum adiponectin levels in Japanese male patients with Type 2 diabetes. Metabolism 51(3), 314–317 (2002).
  • Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum. Reprod. 18(8), 1618–1625 (2003).
  • Belcher G, Matthews DR. Safety and tolerability of pioglitazone. Exp. Gun. Endocrinol Diabetes 108\(Suppl. 2), S267—S273 (2000).
  • Mathisen AL, Brockley MR. The relationship of HbAlc and weight in the treatment of patients with Type 2 diabetes. Diabetes 49 (Suppl. 1), 117 (2000).
  • Tolman KG. Thiazolidinedione hepatotoxicity: a class effect? int. j Gun. Prac. Suppl 113,29–34 (2000).
  • Coyle D, Palmer AJ, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of Type 2 diabetes mellitus in Canada. PharmacoEconomics 20(1), 31–42 (2002).
  • ••Comprehensive model that incorporatessix of the primary complications associated with diabetes including: hypoglycemia, acute myocardial infarction, stroke, lower extremity amputation, nephropathy and retinopathy. The model integrates the outcomes from clinical trials and what is known from United Kingdom Prospective Diabetes Study (UKPDS) and other studies regarding glucose control and long-term complications in developing cost-effectiveness arguments.
  • Henriksson E Applications of economic models in healthcare: the introduction of pioglitazone in Sweden. PharmacoEconomic520(1), 43–53 (2002).
  • Chilcott J, Wight J. Lloyd Jones M, Tappenden P The clinical effectiveness and cost-effectiveness of pioglitazone for Type 2 diabetes mellitus: a rapid and systematic review. Health Technology Assess. 5(19), 1–61 (2001).
  • •Thorough review of the literature and reviews all of the available data available as of 2001. This work does an excellent job of summarizing the available literature on pioglitazone and its application for economic modelling, and as a critical appraisal of the economic submission to National Institute of Clinical Excellence.
  • Boucher M, McAuley L, Brown A, Keely E, Skidmore B (Canadian Co-ordinating Office for Health Technology Assessment). Efficacy of rosiglitazone and pioglitazone compared to other antidiabetic agents: Systematic review and budget impact analysis. Canadian Co-animating Office for Health Technology Assessment, October (2002)
  • National Institute for Clinical Excellence for the National Health Service. Guidance on the use of pioglitazone for Type 2 diabetes mellitus. Technology Appraisal Guidance, No. 21, March (2001).
  • National Institute for Clinical Excellence for the National Health Service. Guidance on the use of glitazones for the treatment of Type 2 diabetes. 7chnology Appraisal 63, August (2003).
  • Matthews DR, Cul CA, Stratton IM et al. UKPDS 26: sulphonylurea failure in noninsulin-dependant diabetic patients over six years. UK prospective diabetes study (UKPDS) Group. Diabetes Med. 15(4), 297–303 (1998).
  • Palmer AJ, Sendi PP, Spinas GA. Applying some UK prospective diabetes study results to Switzerland: the cost-effectiveness of intensive glycemic control with metformin versus conventional control in overweight patients with type-2 diabetes. Schweiz. Med Wochenschr 130 (27–28), 1034–1040 (2000).
  • •Describes in some detail the methods employed in modeling of UKPDS data and its application in comparing pharmacological interventions in terms of cost-effectiveness based on specific health outcome measures.
  • Chun B, Coyle D, Berthelot JM et al Estimating the cost of coronary heart disease in Manitoba. Proceedings of the American Statistical Association Joint Annual Meeting. (1997)
  • Smurawsksa LT, Alexandrov AV, Bladin CF. Cost of acute stroke care in Toronto, Canada. 9roke25, 1628–1231 (1994).
  • Lapaucais A, Feeney D, Detsky AS et al. How attractive does a new technology have to be to warrant adoption and utilization. Tentative guidelines for using clinical and economic evaluations Can. Med. Assoc. j 146(4), 473–481 (1992).
  • Siddique R, Ricci JA, Stewart WF, Sloan S, Farup CE. Quality of life in a US national sample of adults with diabetes and motility related upper gastrointestinal symptoms. affective Dis. Sciences 47(4), 683–689 (2002).
  • Palmer AJ, Weis C, Sendi P et al. The cost- effectiveness of different management strategies for Type 1 diabetes: a Swiss perspective. Diabetologia 43,13–26 (2000).
  • Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. Can. Med. Assoc. j 148(6), 913–917 (1993).
  • Sendi P, Gafni A, Birch S. Opportunity costs and uncertainty in the economic evaluation of healthcare interventions. Health Economicsll, 23–31 (2002).

Websites

  • Canadian Diabetes Association www.diabetes.ca (Accessed March 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.